hat the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3

With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7

The volume of the temples can diminish with age, which can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance.3,8,9These facial changes can be accelerated in people undergoing me
=*=*=*=*=*=
当前为第2/15页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页